Oventus, an Australian-based medical device company will preview O2Vent device this week at the American Academy of Dental Sleep Medicine events in Denver. Oventus devices have a breathing airway at the front of the appliance that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue, thus targeting patients of Sleep Apnoea and Snoring.

With recently getting the clearance from US FDA for O2VentTM Mono device, Oventus Medical has now successfully registered its listing on the ASX on 19 July 2016 with a fully subscribed IPO. The company’s O2VentTM  range incorporates an airway to bypass nasal, soft palate and tongue obstructions. The company has also registered its next generation O2VentTM T titratable device with the Australian Therapeutic Goods Administration (TGA) and launched the device for consumers through an expanded network of dentists.